Clover Reports Favorable Early Phase I Findings for SCB-1019, a Dual-Target RSV Vaccine, in Young Adults

Clover Biopharmaceuticals, a leading biotech firm, has reported promising initial results from its Phase I clinical trial for SCB-1019, a novel bivalent RSV vaccine. The vaccine significantly increased neutralizing antibody levels against both RSV-A and RSV-B strains, with a 6.4-fold and 11.8-fold rise, respectively. The trial, which included young adults aged 18-59, demonstrated that SCB-1019 is well-tolerated with no significant safety concerns observed. Clover's vaccine candidate, developed using the company's proprietary Trimer-Tag platform, is the first of its kind from China to reach the clinical trial phase and is expected to yield additional data in older adults by the second half of 2024.

The immunogenicity data for SCB-1019 is comparable or potentially superior to other protein subunit RSV vaccines, supporting Clover's dual approach to targeting both RSV-A and RSV-B. This is significant as previous monovalent RSV-A vaccines have shown reduced efficacy against RSV-B. The vaccine's PreF antigens are confirmed to be in a stabilized prefusion trimeric form, which is crucial for effectiveness. The Phase I clinical trial in Australia is a randomized, placebo-controlled study designed to evaluate the safety and immunogenicity of SCB-1019 across different dosages and formulations in both young and older adults.

Clover Biopharmaceuticals is dedicated to developing innovative vaccines to address global health challenges and aims to reduce the impact of vaccine-preventable diseases. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!